New combo therapy shows promise for tough liver cancer

NCT ID NCT04238637

Ongoing Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding immunotherapy drugs (durvalumab and tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults with this rare liver cancer will receive the combination treatment. The goal is to see if the immune system can be boosted to better fight the cancer while radiation targets the tumor directly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma intrahepatic bile duct cancer intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRAHEPATIC CHOLANGIOCARCINOMA

Contacts and locations

Show contact details

Locations

Clinic Essen Center

Essen, Germany
Hannover Medical School

Hanover, Germany
Munich Clinic Bogenhausen

Munich, Germany
University Hospital Dresden

Dresden, Germany
University Hospital Essen

Essen, Germany
University Hospital Halle

Halle, Germany
University Hospital Jena

Jena, Germany
University Hospital Munich Grosshadern

Munich, Germany